Welcome to our dedicated page for Halberd news (Ticker: HALB), a resource for investors and traders seeking the latest updates and insights on Halberd stock.
Halberd Corporation (HALB) is an innovative biopharmaceutical company developing targeted therapies for PTSD, traumatic brain injury, and related mental health conditions through patented drug formulations and wearable monitoring technologies. This news hub provides investors and researchers with timely updates on the company's clinical trials, intellectual property developments, and strategic partnerships.
Access authoritative information about HALB's progress in mental health treatment innovation, including updates on its LDN+ and Tri-Ax nasal spray therapies. The repository consolidates press releases related to CRADA clinical trials, technology integrations with partners like Athena GTX, and patent filings that underpin the company's valuation.
Key content categories include regulatory milestones, research collaborations with military healthcare providers, and advancements in combined pharmaceutical/digital health solutions. All materials maintain compliance with OTC Market disclosure standards while emphasizing HALB's unique position at the intersection of biopharma and wearable diagnostics.
Bookmark this page for streamlined tracking of HALB's progress in addressing critical mental health challenges through evidence-based therapeutic innovation. Check regularly for verified updates that reflect the company's commitment to advancing both patient care and shareholder value.
Halberd Corporation (OTC PINK: HALB) announced a new patent-pending Covid-19 fluorescent antibody aimed at rapid virus detection. CEO William A. Hartman discussed the advantages of this test during a Money TV interview, highlighting its potential for real-time monitoring of Covid-19 status, in contrast to existing passports. The test could significantly benefit the travel and entertainment industries. Moreover, Halberd is developing a nasal spray as both a preventive and therapeutic option against Covid-19, while also working on new developments under provisional patents.
Halberd Corporation (OTC PINK:HALB) has developed a second monoclonal antibody targeting COVID-19 antigens, potentially enhancing the efficacy of their nasal spray treatment. Dr. Mitchell S. Felder filed a provisional patent for this innovation, which aims to reduce viral load and alleviate COVID-19 symptoms. Halberd’s recent advancements reportedly double the performance of their existing antibody. The company plans to expedite research towards animal and human testing to demonstrate safety and efficacy. Currently, there are 317,721,539 outstanding shares.
Halberd Corporation (OTC PINK: HALB) CEO William A. Hartman discussed recent achievements and strategic initiatives in an interview on Money TV. Halberd has partnered with Arizona State University for research and is focused on developing Covid-19 antibodies and related technologies. The company has filed provisional patents for innovative treatments and maintains a debt-free status. Hartman also highlighted potential applications for their technology in various diseases and introduced a prototype for an Anti-Addiction Patch. Halberd aims for significant market success amidst the ongoing pandemic challenges.
Halberd Corporation (OTC PINK: HALB) has announced the development of a new class of anti-Spike protein monoclonal antibodies targeting Covid-19, in collaboration with Arizona State University. They are in the process of filing joint patent applications for this discovery. The engineered antibodies may enable rapid detection of the virus in various samples and on surfaces. This advancement aims to enhance early identification and treatment, potentially curbing the virus's spread. Halberd's CTO highlighted the progress, signaling more patent applications to follow.
Halberd Corporation (OTC PINK: HALB) announced significant advancements in COVID-19 research through collaboration with Arizona State University. Researchers have successfully produced an anti-Spike protein monoclonal antibody targeting the virus, with plans for patent protections. Potential applications include a preventative, diagnostic, and therapeutic treatment. The company aims to provide ongoing updates on the progress of this vital research.
Halberd Corporation (OTC PINK: HALB) has made significant strides since May, focusing on coronavirus detection and treatment. Key achievements include recruiting top talent, securing exclusive licenses for four provisional patents related to COVID-19, and establishing a partnership with a leading university for research. Plans for the upcoming quarter involve in-depth testing of a novel COVID antibody for preventative, diagnostic, and therapeutic purposes. Halberd emphasizes the importance of collaborations with established pharmaceutical firms to expedite product development and FDA certification.
Halberd Corporation (OTC PINK: HALB) has secured a worldwide license for a provisional patent on a nasal spray aimed at preventing the transmission of coronavirus. The spray utilizes an antibody solution to block ACE2 receptors in nasal epithelial cells, potentially reducing the severity of COVID-19. This invention encompasses a protective measure against coronaviruses and aligns with Halberd's ongoing research in combating COVID-19. The company holds exclusive rights to several related patents, enhancing its position in the market for COVID-19 treatments.
Halberd Corporation (OTC PINK: HALB) has obtained exclusive rights to a provisional patent for a nasal spray aimed at preventing COVID-19 transmission. This development is based on research indicating that children have fewer ACE2 receptors, which the virus uses to infect cells. Halberd, in collaboration with Arizona State University, is pursuing a comprehensive approach involving a preventative nasal spray, fast diagnostics, and therapeutic treatments. The company is ready to initiate testing in South America and is seeking partners for pharmaceutical development.
Halberd Corporation (OTC PINK: HALB) has announced a collaborative research project with Arizona State University to develop a rapid diagnostic test for Covid-19. The focus is on the coronavirus spike antigen, which is critical to the virus's contagiousness. Feasibility samples of an antibody conjugate are expected in four weeks, potentially enabling a quick testing method using saliva or blood. The company holds exclusive rights to relevant provisional patents for Covid-19 treatments.
Halberd Corporation (OTC PINK: HALB) announced a significant breakthrough in its COVID-19 research project with Arizona State University. Dr. Qiang Chen's team successfully recreated the coronavirus spike protein disease antigen, paving the way for the identification of proprietary antibodies expected within two weeks. The joint efforts aim to secure patent protections for their findings. The company's patented extracorporeal process could improve detection and treatment of COVID-19 while minimizing side effects associated with traditional drug therapies.
